The Study of Safety and Preliminary Efficacy of ALT001 in Patients With MultIple System Atrophy-Cerebellar Type

This is a single-center, prospective, randomized, open-label, blinded outcome assessment (PROBE) study. At the end of the PROBE study, patients who have completed the study may opt to enter the open-label extension (OLE) study. The objective of the study is to evaluate the safety, tolerability and potential preliminary efficacy of ALT001 in the treatment of patients with multiple system atrophy-cerebellar type (MSA-C).

NCT Number	NCT07514923
Lead Sponsor	yilong Wang
Conditions	Multiple System Atrophy - Cerebellar Subtype (MSA-C)
Enrollment	20 participants
Start Date	2026-04-06
Primary Completion	2027-01-31 (estimated)
Study Completion	2027-10-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-07